Sunday, 9 August 2026
Daraxonrasib demand surges, Latigo raises $345 million, AHPRA privacy breach impacts 136
- 01
High demand for daraxonrasib as compassionate use expands
More than 2,000 patients have received Revolution Medicines’ pancreatic cancer drug daraxonrasib through a compassionate use program, indicating significant demand for the treatment. Analysts project that daraxonrasib could generate up to $1.1 billion in sales by the end of 2027, as it is currently under evaluation by the FDA for expedited review. The drug has been distributed to cancer centres and practices across nearly every state, despite no formal marketing efforts. This development highlights the potential impact of daraxonrasib on treatment options for pancreatic cancer patients.
via BioPharma Dive
- 02
Latigo Biotherapeutics raises $345.6 million in IPO for pain drug development
Latigo Biotherapeutics went public, raising over $345 million to advance its development of non-opioid pain medications. The company sold 19.2 million shares at $18 each, attracting more investor interest than anticipated. Latigo aims to compete in the market for ion-channel-blocking pain drugs, joining a recent surge in biotech IPOs. The company has three drugs in its pipeline, with the most advanced nearing late-stage testing for acute pain treatment.
via BioPharma Dive
- 03
AHPRA privacy breach affects 136 health practitioners
AHPRA confirmed a privacy breach involving 136 health practitioners, including doctors and nurses, who were invited to a webinar without their email addresses being concealed. Federal Health Minister Mark Butler described the incident as a "totally unacceptable" lapse. AHPRA has apologised and taken immediate steps, including notifying affected individuals and advising them on how to file complaints. Legal experts suggest that while there may be potential for defamation claims, successful legal action against AHPRA is unlikely due to the complexities of privacy law.
- 04
Clascoterone cream introduced as a new acne treatment option
Clascoterone cream has emerged as a novel treatment for acne management, according to dermatologist Dr Corinne Maiolo. The cream features a unique mechanism of action that distinguishes it from existing therapies. This development offers clinicians an additional option for managing acne in their patients. The introduction of clascoterone cream could impact treatment strategies in primary care.
- 05
New initiative aims to rebuild vaccine confidence among patients
A new initiative focuses on rebuilding vaccine confidence, emphasising the importance of practical conversations for general practitioners. This effort aims to enhance patient education and support vaccination efforts. The initiative is particularly relevant as GPs play a crucial role in addressing vaccine hesitancy. Details on the specific strategies or resources involved were not provided.
- 06
Dr Ramya Raman Joins Race for RACGP Presidency
Dr Ramya Raman, a candidate for the RACGP presidency, has pledged to cap member fee increases at the MBS rebate indexation if elected. As a long-time WA faculty chair, she emphasises the need for credible evidence and solutions that reflect GPs' realities. Raman advocates for improved training pathways for registrars, particularly in rural areas, and aims to address the challenges of funding and support for supervisors. With voting set to open this Tuesday, her candidacy adds to the ongoing discussion about the future leadership of the RACGP.
MDDR is a news digest for medical professionals. It is not medical advice and should not be relied on for clinical decision-making.